amphiphysin

Clathrin-IN-1 is a inhibitor of clathrin, and inhibits clathrin-mediated endocytosis (CME) by associating with the terminal domain of clathrin. It has the potential for anti-cancer research.

Clathrin-IN-25 is the most effective clathrin terminal domain-amphiphysin inhibitor reported to date.

Dynamin Inhibitory Peptide TFA competitively inhibits the binding of dynamin to amphiphysin, effectively preventing endocytosis. Additionally, this compound impedes the dopamine D3's influence on GABA A receptors [1].

Cell-permeable version of dynamin inhibitory peptide, an inhibitor of the GTPase dynamin that competitively blocks binding of dynamin to amphiphysin, preventing endocytosis. Reduces NMDA receptor internalization.

Dynamin inhibitory peptide, myristoylated acetate is a DynaMin inhibitor to interfere with the binding of amphiphysin with dynamin. DynaMin inhibitory peptide, myristoylated TFA is a membrane-permeant form of the peptide that prevents endocytosis.

Control peptide version of dynamin inhibitory peptide, myristoylated, an inhibitor of the GTPase dynamin that competitively blocks binding of dynamin to amphiphysin, preventing endocytosis. In contrast to dynamin inhibitory peptide, has no significant eff

D15 is a peptide containing a 15-amino acid sequence of dynamitin, acting as an AMPAR endocytosis inhibitor. It effectively obstructs the interaction between dynamitin and amphiphysin 1 and 2. D15 significantly enhances the amplitude of AMPAR excitatory postsynaptic currents (EPSC) in the medium spiny neurons (MSNs) of Sapap3KO mice. It is utilized in research on neuropsychiatric disorders.